Conference Coverage

EMEUNET network of young rheumatologists keeps moving forward


 

As the largest network of young rheumatologists in the world, the Emerging EULAR Network (EMEUNET) is looking forward to this year’s European Congress of Rheumatology to continue to build on what it set out to do as part of its mission – to give young rheumatologists and researchers an active say in education and research.

The rationale for the birth of EMEUNET in 2009 was to provide a network where European young rheumatologists and researchers, no matter where they were based, could access mentoring programs, research funding, and education initiatives, Alessia Alunno, MD, PhD, chair-elect and EMEUNET steering committee member, said in an interview.

Dr. Alessia Alunno

Dr. Alessia Alunno

“This was the main rationale for the creation of EMEUNET, and it remains its main goal now,” said Dr. Alunno, assistant professor and rheumatology consultant in the rheumatology unit at the University of Perugia (Italy).

Since its creation, EMEUNET has already achieved its goal several times over, but there’s certainly no intention for the network to rest on its laurels. One of its major achievements has been to secure a voice in the EULAR Strategy for the next 5 years.

“We are now able to sit at the table with the other EULAR pillars so that the educational offering of EULAR is tailored to meet the needs of young rheumatologists and researchers across Europe,” Dr. Alunno said.

And if the success of an organization can be measured by its membership numbers, then it’s clear that EMEUNET is on the right track.

Each year, membership continues to grow, and at 1,909 members, the 2,000 member milestone is tantalizingly close. This makes EMEUNET the largest network of rheumatologists and researchers, which Dr. Alunno said made the steering committee proud because it is a sign that what EMEUNET offers to members is suitable for more and more people.

Pages

Recommended Reading

High testosterone in postmenopausal women may add CVD risk
MDedge Rheumatology
ACS: Screen for colon cancer at 45
MDedge Rheumatology
TAILORx: Most women with intermediate risk ER+ breast cancer can safely skip chemo
MDedge Rheumatology
Hydroxychloroquine throws off Quantiferon-TB Gold results, study finds
MDedge Rheumatology
Hip pain predicts arthritis mortality beyond comorbidities
MDedge Rheumatology
Prostate cancer risk before age 55 higher for black men
MDedge Rheumatology
Statin effect in prostate cancer may be caused by reduced inflammation
MDedge Rheumatology
Raised LDL cholesterol, hsCRP tied to polymyalgia rheumatica, GCA
MDedge Rheumatology
Smoking tied to localized prostate cancer recurrence, metastasis, death
MDedge Rheumatology
FDA approves rituximab for treating pemphigus vulgaris
MDedge Rheumatology